安若维他药业泰州有限公司

The registered capital of Aurovitas Pharma Taizhou Co., Ltd. is 35 million USD, and it is invested by Holland Helix Co., Ltd.. Helix is an internationally renowned large multinational company. Our group is a leader in generic drug research and development. It has registered more than 400 products in USA and nearly 2000 products in EU countries. Our group's products include: central nervous system, anti-HIV virus, cardiovascular, diabetes, gastrointestinal tract, cephalosporins and so on. Our group has factories or offices in China, USA, India, Saudi Arabia, Europe, South America and South Africa, with more than 18,000 employees worldwide. In January 2018, Aurovitas Pharma Taizhou Co., Ltd. was registered in CMC(China Medical City). The company is mainly engaged in the production and R&D of solid oral dosage. The project covers an area of 64567 ㎡, the project will construct production and ancillary facilities such as QC/R&D comprehensive building, solid formulation workshop and high-rac

2020-10-22 22:22:28